ABSTRACT
ABSTRACT: Vitamin C combined with hydrocortisone is increasingly being used to treat septic patients, even though this treatment regimen is based on questionable evidence. When used, a marked effect on key players of innate immunity would be expected, as sepsis is featured by a dysregulated immune response.Here, we explored the effect of vitamin C and hydrocortisone alone and combined, in an ex vivo human whole-blood model of Escherichia coli- or Staphylococcus aureus-induced inflammation. Inflammatory markers for activation of complement (terminal C5b-9 complement complex [TCC]), granulocytes (myeloperoxidase), platelets (ß-thromboglobulin), cytokines (tumor necrosis factor [TNF], IL-1ß, IL6, and IL-8), and leukocytes (CD11b and oxidative burst) were quantified, by enzyme-linked immunosorbent assay, multiplex technology, and flow cytometry.In E. coli- and S. aureus-stimulated whole blood, a broad dose-titration of vitamin C and hydrocortisone alone did not lead to dose-response effects for the central innate immune mediators TCC and IL-6. Hence, the clinically relevant doses were used further. Compared to the untreated control sample, two of the nine biomarkers induced by E. coli were reduced by hydrocortisone and/or vitamin C. TNF was reduced by hydrocortisone alone (19%, Pâ=â0.01) and by the combination (31%, Pâ=â0.01). The oxidative burst of monocytes and granulocytes was reduced for both drugs alone and their combination, (ranging 8-19%, Pâ<â0.05). Using S. aureus, neither of the drugs, alone nor in combination, had any effects on the nine biomarkers.In conclusion, despite the limitation of the ex vivo model, the effect of vitamin C and hydrocortisone on bacteria-induced inflammatory response in human whole blood is limited and following the clinical data.
Subject(s)
Ascorbic Acid/pharmacology , Escherichia coli/immunology , Hydrocortisone/pharmacology , Staphylococcus aureus/immunology , Biomarkers , CD11b Antigen/blood , Complement Membrane Attack Complex/analysis , Cytokines/blood , Humans , Peroxidase/blood , Respiratory Burst , beta-Thromboglobulin/analysisABSTRACT
Importance: Obesity, particularly visceral obesity and sarcopenia, are poor prognostic indicators in colon cancer. Objectives: To explore the association between body composition profiles and 5-year colon cancer outcomes and delineate the associated underlying inflammatory processes. Design, Setting, and Participants: This multicenter translational cohort study included patients with nonmetastatic colon cancer who did not have underlying chronic inflammatory disorders and were not receiving anti-inflammatory drugs referred to tertiary cancer centers from 2009 to 2015. Preoperative acute phase proteins (white cell count, C-reactive protein, and albumin), cytokines (interleukin [IL]-1b, IL-2, IL-6, IL-10, interferon γ, and tumor necrosis factor α), vascular endothelial growth factor (VEGF), and cell surface receptor expression levels (CD11b and CD14) were measured. All patients underwent follow-up for at least 5 years. Data were analyzed in December 2020. Exposure: Nonmetastatic colon cancer. Main Outcomes and Measures: The associations of body composition profiles with 5-year cancer recurrence and disease-specific mortality were analyzed using Mantel Cox log-rank test and Kaplan-Meier curves. Results: A total of 28 patients were included (median [interquartile range] age, 67 [58-72] years; 22 [78.6%] men). Low skeletal muscle area (SMA) and high visceral to total fat ratio were associated with poor clinical and oncological outcomes, including increased 5-year recurrence (low SMA: hazard ratio [HR], 2.30 [95% CI, 1.41-2.89]; P = .04; high visceral to total fat ratio: HR, 5.78 [95% CI, 3.66-7.95]; P = .02). High visceral to total fat ratio was associated with increased 5-year disease-specific mortality (HR, 5.92 [95% CI, 4.04-8.00]; P = .02). Patients with low SMA who developed a cancer recurrence, compared with those who did not, had higher C-reactive protein (mean [SD], 31.24 [6.95] mg/dL vs 8.11 [0.58] mg/dL; P = .003), IL-6 (mean [SD], 1.93 [1.16] ng/mL vs 0.88 [0.14] ng/mL; P = .004), VEGF (mean [SD], 310.03 [122.66] ng/mL vs 176.12 [22.94] ng/mL; P = .007), and CD14 (mean [SD], 521.23 [302.02] ng/mL vs 322.07 [98.35] ng/mL; P = .03) expression and lower albumin (mean [SD], 3.8 [0.6] g/dL vs 43.50 [3.69] g/dL; P = .01), IL-2 (mean [SD], 0.45 [0.25] ng/mL vs 0.94 [0.43] ng/mL; P < .001), IL-10 (mean [SD], 8.15 [1.09] ng/mL vs 16.32 [4.43] ng/mL; P = .004), and interferon γ (mean [SD], 2.61 [1.36] ng/mL vs 14.87 [3.43] ng/mL; P = .02) levels. Patients with high visceral to total fat ratio who developed recurrence had higher levels of IL-6 (mean [SD], 5.26 [7.05] ng/mL vs 2.76 [3.11] ng/mL; P = .03) and tumor necrosis factor α (mean [SD], 5.74 [4.53] ng/mL vs 4.50 [1.99] ng/mL; P = .03). Conclusions and Relevance: These findings suggest that low SMA and high visceral to total fat ratio were associated with worse colon cancer outcomes and with increased expression of proinflammatory cytokines and VEGF and inhibition of anti-inflammatory cytokines.
Subject(s)
Body Composition , Colonic Neoplasms/mortality , Colonic Neoplasms/physiopathology , Adipose Tissue/physiopathology , Aged , C-Reactive Protein/analysis , CD11b Antigen/blood , Colonic Neoplasms/surgery , Cytokines/blood , Female , Humans , Inflammation , Intra-Abdominal Fat/physiopathology , Kaplan-Meier Estimate , Leukocyte Count , Lipopolysaccharide Receptors/blood , Male , Middle Aged , Muscle, Skeletal/physiopathology , Neoplasm Recurrence, Local/mortality , Neoplasm Recurrence, Local/physiopathology , Preoperative Period , Proportional Hazards Models , Serum Albumin/analysis , Vascular Endothelial Growth Factor A/bloodABSTRACT
Synucleinopathies are neurodegenerative diseases with both central and peripheral immune responses. However, whether the peripheral immune changes occur early in disease and their relation to brain events is yet unclear. Isolated rapid-eye-movement (REM) sleep behavior disorder (iRBD) can precede synucleinopathy-related parkinsonism and provides a prodromal phenotype to study early Parkinson's disease events. In this prospective case-control study, we describe monocytic markers in a cohort of iRBD patients that were associated with the brain-imaging markers of inflammation and neuronal dysfunction. Using 11C-PK11195 positron emission tomography (PET), we previously showed increased immune activation in the substantia nigra of iRBD patients, while 18F-DOPA PET detected reduced putaminal dopaminergic function. Here we describe that patients' blood monocytic cells showed increased expression of CD11b, while HLA-DR expression was decreased compared to healthy controls. The iRBD patients had increased classical monocytes and mature natural killer cells. Remarkably, the levels of expression of Toll-like receptor 4 (TLR4) on blood monocytes in iRBD patients were positively correlated with nigral immune activation measured by 11C-PK11195 PET and negatively correlated with putaminal 18F-DOPA uptake; the opposite was seen for the percentage of CD163+ myeloid cells. This suggesting a deleterious role for TLR4 and, conversely, a protective one for the CD163 expression. We show an association between peripheral blood monocytes and brain immune and dopaminergic changes in a synucleinopathy-related disorder, thus suggesting a cross-talk among periphery and brain during the disease.
Subject(s)
Neurons , Positron-Emission Tomography , REM Sleep Behavior Disorder , Substantia Nigra , Aged , Biomarkers/blood , CD11b Antigen/blood , CD11b Antigen/immunology , Female , HLA-DR Antigens/blood , HLA-DR Antigens/immunology , Humans , Male , Middle Aged , Monocytes/immunology , Monocytes/metabolism , Neurons/immunology , Neurons/metabolism , REM Sleep Behavior Disorder/blood , REM Sleep Behavior Disorder/diagnostic imaging , REM Sleep Behavior Disorder/immunology , Substantia Nigra/diagnostic imaging , Substantia Nigra/immunology , Substantia Nigra/metabolism , Toll-Like Receptor 4/blood , Toll-Like Receptor 4/immunologyABSTRACT
Although AML-M3 (APL) and HLA-DR negative non-APL are characterized by negative HLA-DR antigen, they are different entities with similar morphology in some cases. The aim of this study is the precise, differential diagnosis of APL from HLA-DR negative non-APL by flow cytometry to narrow the diagnosis window. Bone marrow or blood samples of 580 AML patients were analyzed, and flow cytometry and molecular analysis were performed for the diagnosis of blood disorders. In 105 HLA-DR negative AML patients, expression of HLA-DR, CD33, CD117, CD11b, CD64, CD34, CD9 and myeloperoxidase staining pattern were evaluated. Fifty-six patients were diagnosed with APL, and 49 patients were diagnosed with HLA-DR negative non-APL. The APL blasts expressed CD33, CD117, CD64, and CD9 in 100%, 80.3%, 94.6%, and 100% of the cases, respectively. HLA-DR negative non-APL blasts expressed CD33, CD117, CD64 and CD9 in 75.5%, 59.1%, 32.6%, and 73.4% of the cases, respectively. APL cells were negative for HLA-DR, CD11b, and CD34 in 96.4%, 94.6%, and 91.0%, respectively. Blasts in HLA-DR negative non M3-AML were negative for CD11b, CD117, and CD34 in 77.5%, 40.9%, and 22.4%, respectively. We also investigated myeloperoxidase (MPO) staining pattern and found strong diffuse reaction in APL cells while HLA-DR negative non-APL cells showed focal positive reaction. In all of the APL patients, except for one, PML/RARA translocation was positive, and in another case with HLA-DR negative non-APL, PML/RARA and other translocations were not detected. The six-panel combination profile rapidly and specifically identifies APL from other HLA-DR negative AML.
Subject(s)
Biomarkers, Tumor/blood , Flow Cytometry/methods , HLA-DR Antigens/blood , Leukemia, Promyelocytic, Acute/blood , Leukemia, Promyelocytic, Acute/diagnosis , Adolescent , Adult , Antigens, CD34/blood , CD11b Antigen/blood , Child , Child, Preschool , Diagnosis, Differential , Female , Humans , Immunophenotyping , Infant , Leukemia, Promyelocytic, Acute/genetics , Male , Middle Aged , Oncogene Proteins, Fusion/genetics , Peroxidase/blood , Proto-Oncogene Proteins c-kit/blood , Receptors, IgG/blood , Tetraspanin 29/blood , Young AdultABSTRACT
INTRODUCTION: Phagocytes such as granulocytes and monocytes are fundamental players in the innate immune system. Activation of these cells can be quantified by the measurement of activation marker expression using flow cytometry. Analysis of receptor expression on inflammatory cells facilitates the diagnosis of inflammatory diseases and can be used to determine the extent of inflammation. However, several major limitations of this analysis precludes application of inflammation monitoring in clinical practice. Fast and automated analysis would minimalize ex vivo manipulation and allow reproducible processing. The aim of this study was to evaluate a fully automated "load & go" flow cytometer for analyzing activation of granulocytes and monocytes in a clinically applicable setting. METHODS: Blood samples were obtained from 10 anonymous and healthy volunteers between the age of 18 and 65â¯years. Granulocyte and monocyte activation was determined by the use of the markers CD35, CD11b and CD10 measured in the automated AQUIOS CL® "load & go" flow cytometer. This machine is able to pierce the tube caps, add antibodies, lyse and measure the sample within 20â¯min after vena puncture. Reproducibility tests were performed to test the stability of activation marker expression on phagocytes. The expression of activation markers was measured at different time points after blood drawing to analyze the effect of bench time on granulocyte and monocyte activation. RESULTS: The duplicate experiments demonstrate a high reproducibility of the measurements of the activation state of phagocytes. Healthy controls showed a very homogenous expression of activation markers at Tâ¯=â¯0 (immediately after vena puncture). Activation markers on neutrophils were already significantly increased after 1â¯h (Tâ¯=â¯1) depicted as means (95%Cl) CD35: 2.2× (1.5×-2.5×) pâ¯=â¯.028, CD11b: 2.5× (1.7×-3.1×) pâ¯=â¯.023, CD10: 2.5× (2.1×-2.7×) pâ¯=â¯.009) and a further increase in activation markers was observed after 2 and 3â¯h. Monocytes also showed a increase in activation markers in 1â¯h (mean (95%Cl) CD35: 1.8× (1.3×-2.2×) pâ¯=â¯.058, CD11b: 2.13× (1.6×-2.4×) pâ¯=â¯.025) and also a further significant increase in 2 and 3â¯h was observed. CONCLUSION: This study showed that bench time of one hour already leads to a significant upregulation and bigger variance in activation markers of granulocytes and monocytes. In addition, it is likely that automated flow cytometry reduces intra-assay variability in the analysis of activation markers on inflammatory cells. Therefore, we found that it is of utmost importance to perform immune activation analysis as fast as possible to prevent drawing wrong conclusions. Automated flow cytometry is able to reduce this analysis from 2â¯h to only 15-20â¯min without the need of dedicated personnel and in a point-of-care context. This now allows fast and automated inflammation monitoring in blood samples obtained from a variety of patient groups. FUND: This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.
Subject(s)
CD11b Antigen/blood , Flow Cytometry , Immunophenotyping/methods , Leukocytes/metabolism , Neprilysin/blood , Point-of-Care Systems , Point-of-Care Testing , Receptors, Complement 3b/blood , Adolescent , Adult , Aged , Automation, Laboratory , Biomarkers/blood , Female , Flow Cytometry/instrumentation , Healthy Volunteers , Humans , Immunophenotyping/instrumentation , Leukocytes/immunology , Male , Middle Aged , Monocytes/immunology , Monocytes/metabolism , Neutrophil Activation , Neutrophils/immunology , Neutrophils/metabolism , Phagocytes/immunology , Phagocytes/metabolism , Phenotype , Predictive Value of Tests , Reproducibility of Results , Time Factors , Workflow , Young AdultABSTRACT
Cardiovascular disease is the major cause of mortality among patients with the autoimmune disorder systemic lupus erythematosus (SLE). Our laboratory previously reported that immunosuppression with mycophenolate mofetil, a common therapy in patients with SLE, attenuates the development of hypertension in an experimental model of SLE. Cyclophosphamide (CYC) is another common therapy for patients with SLE that has contributed to improved disease management; however, its impact on the development of hypertension associated with SLE is not clear. We tested whether treatment with CYC (25 mg/kg, once/week, IP injection) for 4 weeks would attenuate hypertension in an established female mouse model of SLE with hypertension (30-week-old NZBWF1 females). Plasma anti-dsDNA IgG levels, pathogenic for the disease, were lower in CYC-treated SLE mice compared to vehicle-treated SLE mice, suggesting efficacy of the therapy to suppress aberrant immune system function. Mean arterial pressure (MAP) was assessed by carotid artery catheters in conscious mice. Treatment did not attenuate the development of hypertension when compared to vehicle-treated SLE mice; however, urinary albumin excretion was lower in CYC-treated animals. Corresponding with the reduction in autoantibodies, data suggest that CYC treatment lowered circulating CD45R+ B cells. Paradoxically, circulating CD11b+ Ly6G+ neutrophils were increased in CYC-treated SLE mice compared to vehicle treated. Estrus cycling data also suggest that CYC treatment had an impact on ovarian function that may be consistent with reduced circulating estrogen levels. Taken together, these data suggest that CYC treatment attenuates autoantibody production and renal disease during SLE, but that the potential to affect MAP may be blunted by the increase in circulating neutrophils and CYC's impact on ovarian function.
Subject(s)
Arterial Pressure/drug effects , Autoimmunity/drug effects , Cyclophosphamide/pharmacology , Hypertension/prevention & control , Immunosuppressive Agents/pharmacology , Kidney/drug effects , Lupus Erythematosus, Systemic/drug therapy , Lupus Nephritis/prevention & control , Ovary/drug effects , Animals , Antibodies, Antinuclear/blood , Antigens, Ly/blood , B-Lymphocytes/drug effects , B-Lymphocytes/immunology , B-Lymphocytes/metabolism , Biomarkers/blood , CD11b Antigen/blood , Disease Models, Animal , Estrogens/blood , Estrus/drug effects , Female , Hypertension/blood , Hypertension/immunology , Hypertension/physiopathology , Kidney/immunology , Kidney/metabolism , Kidney/physiopathology , Leukocyte Common Antigens/blood , Lupus Erythematosus, Systemic/blood , Lupus Erythematosus, Systemic/immunology , Lupus Erythematosus, Systemic/physiopathology , Lupus Nephritis/blood , Lupus Nephritis/immunology , Lupus Nephritis/physiopathology , Mice, Inbred NZB , Neutrophils/drug effects , Neutrophils/immunology , Neutrophils/metabolism , Ovary/immunology , Ovary/metabolism , Ovary/physiopathologyABSTRACT
OBJECTIVES: Our study aimed to synthesise and analyse the early diagnostic value of neutrophil CD11b (nCD11b) for neonatal sepsis. DESIGN: Systematic review and meta-analysis. METHODS: Pubmed, Embase, the Cochrane Library and Web of Science Databases were searched up to June 2018. We used Stata software (V.14.0) to conduct the pooled sensitivity, specificity, positive likelihood ratio (PLR), negative likelihood ratio (NLR), diagnostic OR (DOR), pretest probability, post-test probability and summary receiver operating characteristic (SROC) curve for diagnostic efficiency of n CD11b. RESULTS: Nine studies, accounting for 843 neonates, were included. The overall pooled sensitivity, specificity, PLR, NLR, DOR, post-test positive probability and post-test negative probability and the area under the SROC curve were 0.82 (95% CI 0.71 to 0.90), 0.93 (95% CI 0.62 to 0.99), 11.51 (95% CI 1.55 to 85.62), 0.19 (95% CI 0.10 to 0.36), 59.50 (95% CI 4.65 to 761.58), 74%, 5% and 0.90, which had accuracy in diagnosing neonatal sepsis. CONCLUSION: The present evidence indicated that nCD11b is a promising biomarker for the early diagnosis of neonatal sepsis.
Subject(s)
CD11b Antigen/blood , Neonatal Sepsis/blood , Neonatal Sepsis/diagnosis , Neutrophils/metabolism , Biomarkers/blood , Early Diagnosis , Humans , Infant, Newborn , Neonatal Sepsis/immunologyABSTRACT
BACKGROUND: Nitrogen-containing bisphosphonates (BIS) are potent therapeutics in osteoporosis, but their use may result in osteonecrotic side-effects in the maxillofacial region. Periosteal microcirculatory reactions may contribute to the development of bone-healing complications, particularly in osteoporotic bones, where ischemia-reperfusion (IR) events often develop during orthopaedic/trauma interventions. The effect of BIS on the inflammatory reactions of appendicular long bones has not yet been evaluated; thus, we aimed to examine the influence of chronic zoledronate (ZOL) administration on the periosteal microcirculatory consequences of hindlimb IR in osteopenic rats. MATERIALS AND METHODS: Twelve-week-old female Sprague-Dawley rats were ovariectomized (OVX) or sham-operated, and ZOL (80 µg/kg iv, weekly) or a vehicle was administered for 8 weeks, 4 weeks after the operation. At the end of the pre-treatment protocols, 60-min limb ischemia was induced, followed by 180-min reperfusion. Leukocyte-endothelial interactions were quantitated in tibial periosteal postcapillary venules by intravital fluorescence videomicroscopy. CD11b expression of circulating polymorphonuclear leukocytes (PMN, flow cytometry) and plasma TNF-alpha levels (ELISA) were also determined. Two-way RM ANOVA followed by the Holm-Sidak and Dunn tests was used to assess differences within and between groups, respectively. RESULTS: Limb IR induced significant increases in PMN rolling and firm adhesion in sham-operated and OVX rats, which were exacerbated temporarily in the first 60 min of reperfusion by a ZOL treatment regimen. Postischemic TNF-alpha values showed a similar level of postischemic elevations in all groups, whereas CD11b expression only increased in rats not treated with ZOL. CONCLUSIONS: The present data do not show substantial postischemic periosteal microcirculatory complications after chronic ZOL treatment either in sham-operated or OVX rats. The unaltered extent of limb IR-induced local periosteal microcirculatory reactions in the presence of reduced CD11b adhesion molecule expression on circulating PMNs, however, may be attributable to local endothelial injury/activation caused by ZOL.
Subject(s)
Bone Density Conservation Agents/pharmacology , Hindlimb/blood supply , Microcirculation/drug effects , Reperfusion Injury/physiopathology , Zoledronic Acid/pharmacology , Animals , Bone Diseases, Metabolic/blood , Bone Diseases, Metabolic/drug therapy , CD11b Antigen/blood , Cell Adhesion/drug effects , Cell Adhesion/physiology , Female , Neutrophils/drug effects , Neutrophils/physiology , Ovariectomy , Periosteum/blood supply , Periosteum/drug effects , Rats, Sprague-Dawley , Reperfusion Injury/bloodABSTRACT
OBJECTIVE: To investigate the effects of different doses of curcumin on the levels of immune factors CD11b and CD19 in peripheral blood of heat stroke rats in a simulation dry-heat environment. METHODS: 160 SPF healthy male Sprague-Dawley (SD) rats were selected and divided into different groups according to random number table method: normal saline (NS) control group (given NS), solvent control group [given sodium carboxymethylcellulose (CMCNa)], and curcumin low, medium and high dose pretreatment group (given 0.05, 0.10, 0.20 mg/g of curcumin+0.5% CMCNa solution). There were 32 rats in each group, and were challenged only by 10 mL×kg-1×d-1 lavage, and continuous dosing for 7 days. On the 8th day, rats were challenged at ambient temperature (41.0±0.5) centigrade, relative humidity (10±1)% of the northwest in the special environment of artificial lab, placed in 0 (normal temperature), 50, 100 and 150 minutes respectively. The levels of CD19 and CD11b in peripheral blood of each rat were detected by flow cytometry instrument. RESULTS: With the extension of time in the simulated dry and heat environment, the level of CD11b in peripheral blood was gradually increased in each group, and the peak value was reached at 150 minutes, the NS control group, solvent control group and curcumin low, medium and high dose pretreatment groups were 0.346±0.013, 0.342±0.013, 0.342±0.012, 0.325±0.012, and 0.281±0.012, respectively. In each group, the level of CD19 was first increased and then decreased, reaching its peak value at 100 minutes, and the level of the NS control group, solvent control group and curcumin low, medium and high dose pretreatment groups were 0.586±0.010, 0.601±0.014, 0.684±0.009, 0.613±0.012 and 0.604±0.006, respectively. The level of CD11b in the curcumin medium and high dose pretreatment groups were significantly lower than those in the NS control group and solvent control group (50 minutes: 0.237±0.011, 0.188±0.006 vs. 0.283±0.009, 0.289±0.012; 100 minutes: 0.260±0.010, 0.248±0.008 vs. 0.293±0.008, 0.290±0.007, all P < 0.05), and after placement for 150 minutes, the level of CD11b in the curcumin high dose pretreatment group was significantly lower than that in the NS control group, solvent control group and curcumin low dose pretreatment group (0.281±0.012 vs. 0.346±0.013, 0.342±0.013, 0.342±0.012, all P < 0.05). The level of CD19 in the curcumin low, medium and high dose pretreatment groups were significantly higher than those in the NS control group and solvent control group at 50 minutes in the dry and hot environment (0.394±0.001, 0.436±0.009, 0.553±0.011 vs. 0.205±0.005, 0.197±0.003, all P < 0.05), at 100 minutes, the level of CD19 in the curcumin low dose pretreatment group was significantly higher than that in the NS control group and solvent control group (0.684±0.009 vs. 0.586±0.010, 0.601±0.014, both P < 0.05), there was no significant difference in CD19 level between the other dose pretreatment groups and NS control group; at 150 minutes, there was no significant difference in CD19 level between the curcumin pretreatment groups, the NS control group, and the solvent control group. The peripheral blood immune factors CD11b and CD19 levels in the NS control group and solvent control group were not significantly changed, and there was no significant difference between two groups. CONCLUSIONS: Curcumin pretreatment can reduce the level of CD11b and increase the level of CD19 in peripheral blood of rats with dry heat stroke in the early and middle stages, which may enhance the heat resistance and prevent the occurrence of multiple organ dysfunction by increasing the body immunity, and this effect has nothing to do with the dose of curcumin.
Subject(s)
Antigens, CD19/blood , CD11b Antigen/blood , Curcumin/pharmacology , Heat Stroke/drug therapy , Animals , Heat Stroke/blood , Male , Random Allocation , Rats , Rats, Sprague-Dawley , Treatment OutcomeABSTRACT
Interleukin-17 receptor B (IL-17RB), a member of the IL-17 receptor family activated by IL-17B/IL-17E, has been shown to be involved in inflammatory diseases. However, the regulation and function of IL-17RB in Helicobacter pylori (H. pylori) infection, especially in the early-phase is still unknown. Here, we found that gastric IL-17RB mRNA and protein were decreased in gastric mucosa of both patients and mice infected with H. pylori. In vitro experiments show that IL-17RB expression was down regulated via PI3K/AKT pathway on gastric epithelial cells (GECs) stimulated with H. pylori in a cagA-involved manner, while in vivo studies showed that the effect was partially dependent on cagA expression. IL-17E was also decreased during the early-phase of H. pylori infection, and provision of exogenous IL-17E resulted in increased CD11b+CD11c- myeloid cells accumulation and decreased bacteria colonization within the gastric mucosa. In the early-phase of H. pylori infection, IL-17E-IL-17RB promoted gastric epithelial cell-derived CXCL1/2/5/6 to attract CD11b+CD11c- myeloid cells, and also contributed to host defense by promoting the production of antibacterial protein Reg3a. This study defines a negative regulatory network involving IL-17E, GECs, IL-17RB, CD11b+CD11c- myeloid cells, and Reg3a in the early-phase of H. pylori infection, which results in an impaired host defense within the gastric microenvironment, suggesting IL-17RB as a potential early intervening target in H. pylori infection.
Subject(s)
CD11b Antigen/immunology , CD11c Antigen/immunology , Gastric Mucosa/immunology , Helicobacter Infections/immunology , Helicobacter pylori/isolation & purification , Myeloid Cells/immunology , Receptors, Interleukin-17/immunology , Animals , CD11 Antigens/biosynthesis , CD11 Antigens/immunology , CD11b Antigen/biosynthesis , CD11b Antigen/blood , CD11c Antigen/biosynthesis , Helicobacter Infections/blood , Helicobacter Infections/genetics , Helicobacter pylori/genetics , Humans , Mice , Mice, Inbred C57BL , RNA, Messenger/genetics , RNA, Messenger/immunology , Receptors, Interleukin-17/biosynthesis , Receptors, Interleukin-17/geneticsABSTRACT
BACKGROUND: Platelets store large amounts of serotonin that they release during thrombus formation or acute inflammation. This facilitates hemostasis and modulates the inflammatory response. METHODS: Infarct size, heart function, and inflammatory cell composition were analyzed in mouse models of myocardial reperfusion injury with genetic and pharmacological depletion of platelet serotonin. These studies were complemented by in vitro serotonin stimulation assays of platelets and leukocytes in mice and men, and by measuring plasma serotonin levels and leukocyte activation in patients with acute coronary syndrome. RESULTS: Platelet-derived serotonin induced neutrophil degranulation with release of myeloperoxidase and hydrogen peroxide (H2O2) and increased expression of membrane-bound leukocyte adhesion molecule CD11b, leading to enhanced inflammation in the infarct area and reduced myocardial salvage. In patients hospitalized with acute coronary syndrome, plasmatic serotonin levels correlated with CD11b expression on neutrophils and myeloperoxidase plasma levels. Long-term serotonin reuptake inhibition-reported to protect patients with depression from cardiovascular events-resulted in the depletion of platelet serotonin stores in mice. These mice displayed a reduction in neutrophil degranulation and preserved cardiac function. In line, patients with depression using serotonin reuptake inhibition, presented with suppressed levels of CD11b surface expression on neutrophils and lower myeloperoxidase levels in blood. CONCLUSIONS: Taken together, we identify serotonin as a potent therapeutic target in neutrophil-dependent thromboinflammation during myocardial reperfusion injury.
Subject(s)
Blood Platelets/metabolism , Cell Degranulation , Myocardial Infarction/blood , Myocardial Reperfusion Injury/blood , Myocardium/metabolism , Neutrophils/metabolism , Serotonin/blood , Acute Coronary Syndrome/blood , Animals , CD11b Antigen/blood , Case-Control Studies , Disease Models, Animal , Humans , Hydrogen Peroxide/blood , Mice, Inbred C57BL , Mice, Knockout , Myocardial Infarction/pathology , Myocardial Reperfusion Injury/pathology , Myocardium/pathology , Neutrophils/pathology , Peroxidase/blood , Tryptophan Hydroxylase/deficiency , Tryptophan Hydroxylase/geneticsABSTRACT
Immunoglobulin A vasculitis (IgAV) is an immune complex, small vessel vasculitis with dominant IgA deposits in vessel walls, predominantly affecting the pediatric population. However, adults frequently have more severe gastrointestinal tract (GIT) and renal involvements as compared to children. Our aim was to study serological and cellular biomarkers to support clinicians in their diagnosis and the course of IgAV in adult patients. This cross-sectional study included 62 adult IgAV patients and 53 healthy blood donors (HBDs). Demographic and clinical data, as well as routine laboratory tests, were meticulously analyzed. Serum levels of IL-1ß, IL-2, IL-6, IL-8, IL-9, IL-10, IL-17A, IL-23, TNF-α and serum amyloid A (SAA) were measured. Percentages of neutrophils, lymphocytes, and monocytes with neutrophil expression of L-selectin and integrin αM were determined by flow cytometry. SAA (12-fold), IL-6 (3-fold), IL-8 (2-fold), and TNF-α (2-fold) were significantly elevated in sera of adult IgAV patients compared to HBDs. There was a 16% elevation in neutrophils in IgAV patients, with IgAV neutrophils showing significantly higher CD62L surface expression. IgAV patients with GIT involvement exhibited elevated numbers of leukocytes, neutrophils, and neutrophil/lymphocyte (NLR), but lower neutrophil CD11b expression, as compared to IgAV patients without GIT. IgAV patients exhibit a low-medium grade inflammatory, neutrophil-driven response. Patients with GIT can be distinguished by their elevated NLR.
Subject(s)
Cytokines/blood , IgA Vasculitis/blood , Immunoglobulin A/blood , Neutrophils/metabolism , Adult , Aged , Biomarkers/blood , CD11b Antigen/blood , Case-Control Studies , Cross-Sectional Studies , Female , Flow Cytometry , Humans , IgA Vasculitis/immunology , Immunoglobulin A/immunology , L-Selectin/blood , Male , Middle AgedABSTRACT
OBJECTIVE: To investigate the immunophenotypic characteristics of acute promyelocytic leukemia (APL) and explore the sensitivity and specificity of various antibody combinations for the timely and accurate diagnosis APL. METHODS: A retrospective analysis was performed using morphological, immunological, genetic, and molecular biological data from 92 patients diagnosed with APL and 190 controls diagnosed with non-APL acute myeloid leukemia. RESULTS: For APL diagnosis, the CD9/CD11b/human leukocyte antigen (HLA)-DR antibody combination had 85% sensitivity and 95% specificity, AUC = 0.85. However, the sensitivity and specificity were 39% and 92%, AUC = 0.65, respectively, for the HLA-DR/CD34/CD117 combination, and 80% and 80%, AUC = 0.80, respectively for the CD11b/HLA-DR combination. Significant differences were observed between the different antibody combinations. CONCLUSIONS: The CD9/CD11b/HLA-DR antibody combination displays high sensitivity and specificity and can be used to diagnose APL.
Subject(s)
Antigens, CD19/blood , CD11b Antigen/blood , HLA-DR Antigens/blood , Immunophenotyping , Leukemia, Promyelocytic, Acute , Neoplasm Proteins/blood , Adolescent , Adult , Aged , Aged, 80 and over , Female , Humans , Leukemia, Promyelocytic, Acute/blood , Leukemia, Promyelocytic, Acute/diagnosis , Male , Middle AgedABSTRACT
BACKGROUND: Down syndrome (DS) is the most common syndromic immunodeficiency with an increased risk of infection, mortality from sepsis, and autoinflammation. Innate immune function is altered in DS and therefore we examined responses in CD11b and Toll like receptor 4 (TLR-4), which are important immune cell surface markers upregulated in response to Lipopolysaccharide (LPS) endotoxin, and the immunomodulator melatonin. Neutrophil and monocyte responses to LPS and melatonin in children with Down syndrome (DS) who were clinically stable were compared to age-matched controls. Whole blood was incubated with LPS and melatonin and the relative expression of CD11b and TLR-4 evaluated by flow cytometry. RESULTS: Children with DS had an increased response to LPS in neutrophils and intermediate monocytes, while also having elevated TLR-4 expression on non-classical monocytes compared to controls at baseline. Melatonin reduced CD11b expression on neutrophils, total monocytes, both classical and intermediate sub-types, in children with DS and controls. CONCLUSION: Melatonin could represent a useful clinical adjunct in the treatment of sepsis as an immunomodulator. Children with DS had increased LPS responses which may contribute to the more adverse outcomes seen in sepsis.
Subject(s)
CD11b Antigen/blood , Down Syndrome/immunology , Lipopolysaccharides/immunology , Melatonin/immunology , Toll-Like Receptor 4/blood , Child , Child, Preschool , Escherichia coli/immunology , Female , Humans , Immunologic Factors/therapeutic use , Immunomodulation , Male , Melatonin/therapeutic use , Monocytes/immunology , Neutrophils/immunology , Sepsis/immunology , Sepsis/mortality , Sepsis/therapyABSTRACT
PURPOSE: To examine the impact of polyphenol supplementation on the recruitment, mobilization, and activation of monocyte subsets after resistance exercise. METHODS: Thirty-eight recreationally active males (22.1 ± 3.1 yr; 173.9 ± 7.9 cm; 77.8 ± 14.5 kg) were assigned to 28 d of polyphenol blend (PPB) supplementation, placebo (PL), or control (CON). Blood samples were obtained before (PRE) postresistance exercise, immediately (IP) postresistance exercise, 1 h (1H) postresistance exercise, 5 h (5H) postresistance exercise, 24 h (24H) postresistance exercise, and 48 h (48H) postresistance exercise (PPB/PL) or rest (CON). Fine-needle biopsies were obtained from the vastus lateralis at PRE, 1H, 5H, and 48H. Circulating concentrations of macrophage chemoattractant protein-1 (MCP-1) and fractalkine, as well as intramuscular MCP-1 were analyzed via multiplex assay. Changes in the proportions and expression of CD11b on monocyte subsets were assessed via flow cytometry. RESULTS: Circulating MCP-1 increased in PPB and PL at IP with further increases at 5H. Intramuscular MCP-1 was increased at 1H, 5H, and 48H in all groups. Classical monocyte proportions were reduced in PPB and PL at IP, and increased at 1H. Nonclassical monocytes were increased in PPB and PL at IP, whereas intermediate monocytes were increased at IP, and reduced at 1H. Intermediate monocytes were increased in PPB at 24H and 48H. CD11b expression was reduced on PPB compared with PL and CON at PRE on intermediate and nonclassical monocytes. CONCLUSIONS: Resistance exercise may elicit selective mobilization of intermediate monocytes at 24H and 48H, which may be mediated by tissue damage. Additionally, polyphenol supplementation may suppress CD11b expression on monocyte subsets at rest.
Subject(s)
Antioxidants/administration & dosage , Dietary Supplements , Monocytes/metabolism , Polyphenols/administration & dosage , Quadriceps Muscle/metabolism , Resistance Training , CD11b Antigen/blood , Chemokine CCL2/blood , Chemokine CCL2/metabolism , Chemokine CX3CL1/blood , Humans , Macrophage-1 Antigen/blood , Male , Time Factors , Young AdultABSTRACT
Objective- Nbeal2-/- mice, a model of human gray platelet syndrome, have reduced neutrophil granularity and impaired host defense against systemic Staphylococcus aureus infection. We here aimed to study the role of Nbeal2 deficiency in both leukocytes and platelets during gram-negative pneumonia and sepsis. Approach and Results- We studied the role of Nbeal2 in platelets and leukocytes during murine pneumonia and sepsis by Klebsiella pneumoniae. Apart from platelet α-granule deficiency and reduced neutrophil granularity, also monocyte granularity was reduced in Nbeal2-/- mice, whereas plasma levels of MPO (myeloperoxidase), elastase, NGAL (neutrophil gelatinase-associated lipocalin), and MMP-9 (matrix metalloproteinase 9), and leukocyte CD11b expression were increased. Nbeal2-/- leukocytes showed unaltered in vitro antibacterial response and phagocytosis capacity against Klebsiella, and unchanged reactive nitrogen species and cytokine production. Also during Klebsiella pneumonia and sepsis, Nbeal2-/- mice had similar bacterial growth in lung and distant body sites, with enhanced leukocyte migration to the bronchoalveolar space. Despite similar infection-induced inflammation, organ damage was increased in Nbeal2-/- mice, which was also seen during endotoxemia. Platelet-specific Nbeal2 deficiency did not influence leukocyte functions, indicating that Nbeal2 directly modifies leukocytes. Transfusion of Nbeal2-/- but not of Nbeal2+/+ platelets into thrombocytopenic mice was associated with bleeding in the lung but similar host defense, pointing at a role for platelet α-granules in maintaining vascular integrity but not host defense during Klebsiella pneumosepsis. Conclusions- These data show that Nbeal2 deficiency-resulting in gray platelet syndrome-affects platelets, neutrophils, and monocytes, with intact host defense but increased organ damage during gram-negative pneumosepsis.
Subject(s)
Blood Platelets/metabolism , Blood Proteins/deficiency , Gray Platelet Syndrome/metabolism , Klebsiella Infections/metabolism , Klebsiella pneumoniae/pathogenicity , Multiple Organ Failure/metabolism , Pneumonia, Bacterial/metabolism , Sepsis/metabolism , Animals , Blood Platelets/microbiology , Blood Proteins/genetics , CD11b Antigen/blood , Disease Models, Animal , Female , Gray Platelet Syndrome/blood , Gray Platelet Syndrome/genetics , Host-Pathogen Interactions , Klebsiella Infections/blood , Klebsiella Infections/genetics , Klebsiella Infections/microbiology , Klebsiella pneumoniae/growth & development , Lipocalin-2/blood , Male , Matrix Metalloproteinase 9/blood , Mice, Inbred C57BL , Mice, Knockout , Monocytes/metabolism , Monocytes/microbiology , Multiple Organ Failure/blood , Multiple Organ Failure/genetics , Multiple Organ Failure/microbiology , Neutrophils/metabolism , Neutrophils/microbiology , Pancreatic Elastase/blood , Peroxidase/blood , Platelet Glycoprotein GPIb-IX Complex/genetics , Platelet Glycoprotein GPIb-IX Complex/metabolism , Platelet Transfusion , Pneumonia, Bacterial/blood , Pneumonia, Bacterial/genetics , Pneumonia, Bacterial/microbiology , Sepsis/blood , Sepsis/genetics , Sepsis/microbiologyABSTRACT
The effect of physical activity on the immune system is still poorly understood in cases of systemic lupus erythematosus (SLE). Therefore, our aim was to investigate differences in the serum levels of cytokines (IL-2, IL-5, IL-6, IL-8, IL-10 and TNF-α) and the numbers of CD11b + and CXCR2 + neutrophils and lymphocytes in women with SLE undergoing drug treatment, without ( n = 9) or with ( n = 5) 4 months of kinesiotherapy. Parameters related to functional capacity were also analyzed. In the case of the patients who were not submitted to kinesiotherapy, there were reductions in the levels of IL-5, IL-6 and IL-10, and an increase in the number of CD11b + leukocytes, in addition to an increase in abdominal circumference after the monitoring time. Patients submitted to kinesiotherapy did not present changes in serum cytokines or in the numbers of CD11b + and CXCR2 + neutrophils and lymphocytes, but there were increases of flexibility and strength, as well as a reduction in pain sensation after the monitoring time. In conclusion, kinesiotherapy was able to increase flexibility and reduce pain in SLE patients without influencing immune parameters.
Subject(s)
CD11b Antigen/blood , Interleukin-10/blood , Kinesiology, Applied/methods , Lupus Erythematosus, Systemic/therapy , Lymphocytes/immunology , Pain/prevention & control , Adult , Exercise , Humans , Lupus Erythematosus, Systemic/immunology , Lupus Erythematosus, Systemic/physiopathology , Middle Aged , Prospective Studies , Receptors, Interleukin-8B/bloodABSTRACT
BACKGROUND: Patients with chronic kidney disease (CKD) show elevated levels of inflammatory markers and have an increased risk of infections as well as cardiovascular morbidity. Recent studies have implied effects of fibroblast growth factor 23 (FGF23) on inflammation in CKD. We analyzed potential correlations between levels of FGF23 with pro-inflammatory chemokines and markers of leukocyte transmigration in CKD patients. METHODS: One hundred three patients with CKD 2-5ND and 54 healthy controls, had biochemical markers in blood and urine analyzed according to routine protocol. Pro-inflammatory cytokines were analyzed by Milliplex technique and leukocyte CD11b adhesion molecule expression was measured by flow cytometry. FGF23 levels were measured with ELISA technique. Treatment of leukocytes from healthy blood donors with FGF23 was performed in vitro and effects analyzed by flow cytometry. RESULTS: Tumor necrosis factor-alpha, RANTES and interleukin (IL)-12 levels were significantly higher (p = 0.001, p < 0.001, and p < 0.001) in patients with CKD. Elevated FGF23 levels in the CKD group correlated to glomerular filtration rate, parathyroid hormone, urinary albumin excretion and phosphate as well as to IL-12 and RANTES. CD11b expression on resting granulocytes and monocytes, and on activated monocytes, was associated with FGF23. In vitro treatment of leukocytes with FGF23 reduced CD11b expression in resting as well as in formyl-methyinoyl-leucyl-phenylalanine-stimulated granulocytes (p = 0.03). CONCLUSION: FGF23 levels are associated with various inflammatory markers such as pro-inflammatory cytokines and adhesion molecules on innate immune cells. However, further studies are warranted to define the direct role of FGF23 in modulation of the innate immune system in CKD.
Subject(s)
Cell Migration Assays, Leukocyte , Fibroblast Growth Factors/blood , Inflammation/blood , Renal Insufficiency, Chronic/blood , Adolescent , Adult , Biomarkers/blood , Biomarkers/urine , CD11b Antigen/blood , Chemokine CCL5/blood , Cytokines/blood , Cytokines/urine , Female , Fibroblast Growth Factor-23 , Fibroblast Growth Factors/urine , Humans , Inflammation/urine , Interleukin-12/blood , Male , Middle Aged , Renal Insufficiency, Chronic/urine , Respiratory Burst , Young AdultABSTRACT
This study was performed to gain further insight in the heterogeneity of monocytes in the different categories of acute coronary syndrome (ACS), especially between patients with unstable angina pectoris, ST-elevation myocardial infarction (STEMI), and non-ST-elevation myocardial infarction (NSTEMI). For this purpose, blood samples were collected in the acute phase from patients presenting with an ACS. These samples were examined with multiparameter flow cytometry to identify the different monocyte subsets and to analyze the expression of monocyte-associated molecules. Leukocytes, as well as an absolute number of monocytes, showed a clear and significant increase in patients with STEMI. This increase was seen in all subtypes of monocytes. The classical monocytes (CD14++CD16-) of patients with an NSTEMI had a significantly increased CD11b expression when compared to the control group, while these cells showed a decreased expression pattern in STEMI patients. This increased CD11b-expression was also seen in the intermediate monocytes of NSTEMI, while it was almost completely downregulated on the intermediate monocytes of STEMI. Finally, CX3CR1, which is almost exclusively expressed on intermediate and nonclassical monocytes, showed a significant decrease in expression in patients with STEMI. In conclusion, intermediate and nonclassical monocytes have a different immunophenotypic pattern in patients with STEMI versus NSTEMI. These differences reflect the pro-inflammatory state of the monocytes in NSTEMI and can be used as target molecules for novel therapeutic strategies to diminish the migration of proinflammatory monocytes into the myocardial tissue. © 2017 International Society for Advancement of Cytometry.